Here are five insights:
1. The trial is comparing the Intracept Procedure, a minimally invasive treatment for chronic low back pain, to conservative care.
2. The INTRACEPT study will eventually enroll up to 150 patients across 20 U.S. centers. The study builds off of the company’s previous trail, the Surgical Multi-Center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain.
3. Researchers pinpointed the primary efficacy endpoint as the mean change from baseline at three-months postoperation via the Oswestry Disability Index.
4. Steven R. Garfin, MD, orthopedic surgery department chairman at the University of California, San Diego Medical Center, will serve as principal investigator.
5. Dr. Garfin was a previous North American Spine Society president. He has helped design and assess techniques and instruments for spinal disorder treatments.
More articles on MIS:
DePuy Synthes launches 2 MIS devices: 5 things to know
Titan Medical installs Sport Surgical System at Columbia University Medical Center: 5 things to know
Health Alliance Plan of Michigan to cover coflex device: 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.